FDA Approves New Drug for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
The next-generation BTK inhibitor zanubrutinib showed greater progression-free survival and fewer side effects in phase 3 trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.